Review



exome data  (Broad Clinical Labs)


Bioz Verified Symbol Broad Clinical Labs is a verified supplier
Bioz Manufacturer Symbol Broad Clinical Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Broad Clinical Labs exome data
    Exome Data, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 284 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome data/product/Broad Clinical Labs
    Average 95 stars, based on 284 article reviews
    exome data - by Bioz Stars, 2026-05
    95/100 stars

    Images



    Similar Products

    exome data  (Broad Clinical Labs)
    95
    Broad Clinical Labs exome data
    Exome Data, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome data/product/Broad Clinical Labs
    Average 95 stars, based on 1 article reviews
    exome data - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    whole exome sequencing wes data  (Blueprint Genetics)
    86
    Blueprint Genetics whole exome sequencing wes data
    Whole Exome Sequencing Wes Data, supplied by Blueprint Genetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/whole exome sequencing wes data/product/Blueprint Genetics
    Average 86 stars, based on 1 article reviews
    whole exome sequencing wes data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    amniotic fluid clinical whole exome sequencing data qi guo  (Chongqing Key)
    86
    Chongqing Key amniotic fluid clinical whole exome sequencing data qi guo
    Amniotic Fluid Clinical Whole Exome Sequencing Data Qi Guo, supplied by Chongqing Key, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/amniotic fluid clinical whole exome sequencing data qi guo/product/Chongqing Key
    Average 86 stars, based on 1 article reviews
    amniotic fluid clinical whole exome sequencing data qi guo - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    exomes sequencing raw data  (Biotechnology Information)
    86
    Biotechnology Information exomes sequencing raw data
    Exomes Sequencing Raw Data, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exomes sequencing raw data/product/Biotechnology Information
    Average 86 stars, based on 1 article reviews
    exomes sequencing raw data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    exome data  (Macrogen)
    86
    Macrogen exome data
    Exome Data, supplied by Macrogen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome data/product/Macrogen
    Average 86 stars, based on 1 article reviews
    exome data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    exome data  (Novogene)
    86
    Novogene exome data
    Exome Data, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome data/product/Novogene
    Average 86 stars, based on 1 article reviews
    exome data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    exome sequencing wes data  (Broad Clinical Labs)
    95
    Broad Clinical Labs exome sequencing wes data
    Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After <t>whole-exome</t> <t>sequencing,</t> PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).
    Exome Sequencing Wes Data, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome sequencing wes data/product/Broad Clinical Labs
    Average 95 stars, based on 1 article reviews
    exome sequencing wes data - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    saudi arabian large scale combined clinical exome genome sequencing data  (Databank Inc)
    86
    Databank Inc saudi arabian large scale combined clinical exome genome sequencing data
    Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After <t>whole-exome</t> <t>sequencing,</t> PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).
    Saudi Arabian Large Scale Combined Clinical Exome Genome Sequencing Data, supplied by Databank Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/saudi arabian large scale combined clinical exome genome sequencing data/product/Databank Inc
    Average 86 stars, based on 1 article reviews
    saudi arabian large scale combined clinical exome genome sequencing data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    blood brain paired whole exome sequencing data sets  (Broad Clinical Labs)
    95
    Broad Clinical Labs blood brain paired whole exome sequencing data sets
    Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After <t>whole-exome</t> <t>sequencing,</t> PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).
    Blood Brain Paired Whole Exome Sequencing Data Sets, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blood brain paired whole exome sequencing data sets/product/Broad Clinical Labs
    Average 95 stars, based on 1 article reviews
    blood brain paired whole exome sequencing data sets - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    exome seq data  (Biotechnology Information)
    86
    Biotechnology Information exome seq data
    Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After <t>whole-exome</t> <t>sequencing,</t> PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).
    Exome Seq Data, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/exome seq data/product/Biotechnology Information
    Average 86 stars, based on 1 article reviews
    exome seq data - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After whole-exome sequencing, PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).

    Journal: Cell Genomics

    Article Title: Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

    doi: 10.1016/j.xgen.2025.100987

    Figure Lengend Snippet: Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After whole-exome sequencing, PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).

    Article Snippet: The remainder of our genomic analysis relied on whole exome sequencing (WES) data generated by the Broad Institute Genomics Platform.

    Techniques: Sequencing, Clone Assay, Functional Assay, Protein-Protein interactions, Comparison, Mutagenesis